8-K: BioLife Solutions Q2 Revenue Jumps 29%, Raises 2025 Guidance

BioLife Solutions reports strong second-quarter revenue growth driven by cell processing, prompting an upward revision of its full-year 2025 financial outlook.

Summary

• Total revenue for the second quarter of 2025 was $25.4 million, an increase of 29% from $19.7 million in Q2 2024.
• Cell Processing platform revenue reached $23.0 million, up 28% year-over-year.
• GAAP net loss was $15.8 million, primarily due to a non-cash $15.5 million in-process research and development (IPR&D) expense related to the PanTHERA CryoSolutions acquisition.
• Non-GAAP adjusted EBITDA for Q2 2025 was $6.1 million, or 24% of revenue, compared to $3.9 million (20% of revenue) in Q2 2024.
• Full-year 2025 revenue guidance has been raised to $100.0 million $103.0 million, up from previous guidance of $95.5 million $99.0 million.
• Cell Processing platform revenue guidance for 2025 was also raised to $91.0 million $93.0 million.
• Biopreservation media is utilized in over 250 ongoing commercially sponsored clinical trials in the U.S., representing more than 70% market share, including over 30 Phase III trials.
• Biopreservation media is embedded in 16 unique commercial cell and gene therapies (CGTs) as of June 30, 2025.
• The company acquired the remaining 90% of PanTHERA CryoSolutions, Inc. on April 4, 2025.
• The company purchased $2.0 million of convertible notes in Pluristyx, Inc. on July 18, 2025.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to strong revenue growth, significant expansion in adjusted EBITDA margin, and a raised full-year guidance. The GAAP net loss is primarily attributed to a non-cash IPR&D expense from a strategic acquisition, which is a one-time item and does not reflect core operational performance. The company's strong market position in the growing cell and gene therapy sector further contributes to the positive outlook.

Positives

• Total revenue increased by 29% year-over-year in Q2 2025, reaching $25.4 million.
• Cell Processing revenue grew 28% year-over-year, marking the seventh consecutive quarter of sequential growth.
• Non-GAAP adjusted EBITDA significantly expanded to $6.1 million (24% of revenue) in Q2 2025, up from $3.9 million (20% of revenue) in Q2 2024.
• Full-year 2025 revenue guidance was raised to $100.0 million $103.0 million, reflecting strong performance and improved visibility.
• Biopreservation media holds over 70% market share in relevant commercially sponsored clinical trials in the U.S., including nearly 80% of late-stage (Phase III) trials.
• Biopreservation media is embedded in 16 unique commercial cell and gene therapies, with expectations for 10 additional product approvals, geographic expansions, or new indications over the next 12 months.
• The acquisition of PanTHERA CryoSolutions fortifies the company's position as a biopreservation market leader and adds core scientific capabilities.
• Net cash provided by operating activities for the six months ended June 30, 2025, was $9.095 million, a substantial increase from $1.984 million in the same period of 2024.

Negatives

• GAAP net loss from continuing operations increased to $15.8 million in Q2 2025 from $5.6 million in Q2 2024, primarily due to a non-cash IPR&D expense.
• GAAP gross margin decreased slightly to 62% in Q2 2025 from 64% in Q2 2024.
• Non-GAAP adjusted gross margin decreased slightly to 65% in Q2 2025 from 67% in Q2 2024.
• GAAP operating loss from continuing operations widened to $16.6 million in Q2 2025 from $1.3 million in Q2 2024.

Risks

• Forward-looking statements are based on current expectations and beliefs, involving risks and uncertainties that could cause actual results to differ materially.
• A description of certain risks, uncertainties, and other matters can be found in filings with the U.S. Securities and Exchange Commission.

Future Outlook

Management raised its full-year 2025 total revenue guidance to $100.0 million $103.0 million, representing 22% to 25% growth over 2024. Cell Processing platform revenue guidance was also increased to $91.0 million $93.0 million, reflecting 24% to 26% year-over-year growth. The company expects GAAP gross margin in the low 60% range and non-GAAP adjusted gross margin in the mid-60% range, along with a reduction in GAAP net loss and continued expansion of adjusted EBITDA margin compared to 2024.

Management Comments

• "We delivered another strong quarter with cell processing revenue increasing 28% year-over-year and marking our seventh consecutive quarter of sequential growth."
• "Performance was led by our biopreservation media (BPM) franchise, where we saw continued strength across both direct and distributor channels."
• "Notably, customers with approved commercial therapies again represented approximately 40% of total BPM revenue — underscoring the recurring nature of our product and the specd in consistency of our model."
• "With our media embedded in 16 approved therapies and supporting more than 250 ongoing commercial trials, including over 30 in Phase III, we’ve established BioLife as the default partner for clinical programs across all phases, including later stage trials where clinical success is more likely and the path to commercial revenue is clearest."
• "With this momentum and improved visibility into the second half, even against an uncertain macro backdrop, we are raising our full year guidance for cell processing revenue."
• "Continued outperformance in cell processing and meaningful year-over-year expansion in adjusted EBITDA margin reflect the operating leverage and financial benefits of our streamlined operations and focused product portfolio — positioning BioLife to deliver sustained growth and long-term shareholder value."

Industry Context

BioLife Solutions operates as a leading developer and supplier of cell processing tools and services within the rapidly expanding cell and gene therapy (CGT) market. The company's strong market share in biopreservation media for clinical trials (over 70%) and its presence in 16 approved commercial CGTs highlight its critical role in the industry's infrastructure. Strategic acquisitions like PanTHERA CryoSolutions and investments in companies like Pluristyx demonstrate a commitment to expanding its core capabilities and product portfolio to meet the evolving needs of CGT developers, reinforcing its position as a key enabler for the commercialization of new therapies.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct assessment against global benchmarks.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, improved profitability metrics (adjusted EBITDA), and raised full-year guidance, indicating potential for increased shareholder value.
• Customers: Positive impact as the acquisition of PanTHERA CryoSolutions enhances the company's biopreservation solutions, potentially offering more advanced and comprehensive tools for cell and gene therapy development.
• Employees: The streamlined operations and focused product portfolio mentioned by management could imply a stable or improving operational environment, though no direct impact on employment levels is stated.

Next Steps

• Expectations for approvals of 10 additional products, geographic expansions, earlier lines of treatment, or new indications over the next 12 months where biopreservation media is embedded.

Key Dates

Recommendation

The company demonstrated robust financial performance with significant revenue growth and strong adjusted EBITDA expansion. The upward revision of full-year guidance signals management's confidence and positive momentum. BioLife Solutions holds a dominant market position in the critical biopreservation segment of the high-growth cell and gene therapy market, with its products embedded in numerous clinical trials and approved therapies. The non-cash GAAP loss is attributable to a strategic acquisition, which is a long-term positive. These factors collectively suggest strong future potential and make the stock an attractive investment.

Keywords

Cell and Gene Therapy, Biopreservation, Cryopreservation, Cell Processing, Biopreservation Media, CellSeal, hPL, Clinical Trials, Biotechnology, Life Sciences, Medical Devices